Our results demonstrate (based on the percentage of Ki-67+ cells) that CM treatment reduced HCC-515 proliferative potential, which was rescued upon knocking-in of TRPA1 in the presence of FGFR2, but not in FGFR2-knockdown cells (bottom panel). Here, FGFR2 is linked to hepatocellular carcinoma.